The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Is resistance useless? Multidrug resistance and collateral sensitivity
Open accessAbstract
When cancer cells develop resistance to chemotherapeutics, it is frequently conferred by the ATP-dependent efflux pump P-glycoprotein (MDR1, P-gp, ABCB1). P-gp can efflux a wide range of cancer drugs; thus its expression confers cross-resistance, termed multidrug resistance (MDR), to a wide range of drugs. Strategies to overcome this resistance have been actively sought for over 30 years, yet no clinical solutions exist. A less understood aspect of MDR is the hypersensitivity of resistant cancer cells to other drugs, a phenomenon generally known as collateral sensitivity (CS). This review highlights the extent of this effect for the first time, discusses hypotheses such as ROS generation to account for the underlying generality of this phenomenon, and proposes the exploitation of CS as a strategy to improve response to chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
Self-citationWallace, D. C. (2005) · Annual Review of Genetics · doi:10.1146/annurev.genet.39.110304.095751 · Cited by 3,185
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
Self-citationBIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059
Self-citationStructure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., et al. (2009) · Science · doi:10.1126/science.1168750 · Cited by 1,929
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
Localization of the primary metabolic block produced by 2-deoxyglucose
Wick, A. N., Drury, D. R., Nakada, H. I., Wolfe, J. B., Britton, B., & Grabowski, R. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64988-9 · Cited by 780
Tsuruo, T., Iida, H., Tsukagoshi, S., & Sakurai, Y. (1982) · PubMed · Cited by 659
Predicting drug sensitivity and resistance
Szakács, G., Annereau, J.-P., Lababidi, S., Shankavaram, U., Arciello, A., Bussey, K. J., Reinhold, W., Guo, Y., Kruh, G. D., Reimers, M., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.026 · Cited by 531
Self-citationWhitnall, M., Howard, J., Ponka, P., & Richardson, D. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604979103 · Cited by 509
The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy
Hall, M. D., Okabe, M., Shen, D.-W., Liang, X.-J., & Gottesman, M. M. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.080907.180426 · Cited by 474
Self-citationSzybalski, W., & Bryson, V. (1952) · Journal of Bacteriology · doi:10.1128/jb.64.4.489-499.1952 · Cited by 421
Neural Computing in Cancer Drug Development: Predicting Mechanism of Action
Weinstein, J. N., Kohn, K. W., Grever, M. R., Viswanadhan, V. N., Rubinstein, L. V., Monks, A. P., Scudiero, D. A., Welch, L., Koutsoukos, A. D., Chiausa, A. J., et al. (1992) · Science · doi:10.1126/science.1411538 · Cited by 312
Pleiotropic phenotype of colchicine‐resistant CHO cells: Cross‐resistance and collateral sensitivity
Bech‐Hansen, N. T., Till, J. E., & Ling, V. (1976) · Journal of Cellular Physiology · doi:10.1002/jcp.1040880104 · Cited by 309
Iron chelators as therapeutic agents for the treatment of cancer
Richardson, D. R. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00218-9 · Cited by 227
Reversal of multidrug resistance in cancer cells by pyranocoumarins isolated from Radix Peucedani
Wu, J. Y.-C., Fong, W.-F., Zhang, J.-X., Leung, C.-H., Kwong, H.-L., Yang, M.-S., Li, D., & Cheung, H.-Y. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01946-0 · Cited by 221
Variable modulation of opioid brain uptake by P-glycoprotein in mice
Dagenais, C., Graff, C. L., & Pollack, G. M. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.08.027 · Cited by 220
Redox characteristics of the eukaryotic cytosol
López-Mirabal, H. R., & Winther, J. R. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.10.013 · Cited by 207
Richardson, D. R., Kalinowski, D. S., Richardson, V., Sharpe, P. C., Lovejoy, D. B., Islam, M., & Bernhardt, P. V. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801585u · Cited by 200
Ferté, J. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01046.x · Cited by 194
Ludwig, J. A., Szakács, G., Martin, S. E., Chu, B. F., Cardarelli, C., Sauna, Z. E., Caplen, N. J., Fales, H. M., Ambudkar, S. V., Weinstein, J. N., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3322 · Cited by 176
Self-citationHall, M. D., Salam, N. K., Hellawell, J. L., Fales, H. M., Kensler, C. B., Ludwig, J. A., Szakács, G., Hibbs, D. E., & Gottesman, M. M. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800861c · Cited by 167
Self-citationKurtoglu, M., Maher, J. C., & Lampidis, T. J. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1714 · Cited by 163
Rao, V. A., Klein, S. R., Agama, K., Toyoda, E., Adachi, N., Pommier, Y. G., & Shacter, E. B. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1437 · Cited by 156
Steroid Transport, Accumulation, and Antagonism of P-Glycoprotein in Multidrug-Resistant Cells
Barnes, K. M., Dickstein, B., Cutler, G. B., Fojo, T., & Bates, S. E. (1996) · Biochemistry · doi:10.1021/bi952380k · Cited by 154
Bergman, A. M., Pinedo, H. M., Talianidis, I., Veerman, G., Loves, W. J. P., van der Wilt, C. L., & Peters, G. J. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601011 · Cited by 151
Action of calcium antagonists on multidrug resistant cells
Cano-Gauci, D. F., & Riorda, J. R. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90139-0 · Cited by 148
A systematic review of platinum and taxane resistance from bench to clinic: An inverse relationship
Stordal, B., Pavlakis, N., & Davey, R. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.07.013 · Cited by 144
Heffeter, P., Jakupec, M. A., Körner, W., Wild, S., von Keyserlingk, N. G., Elbling, L., Zorbas, H., Korynevska, A., Knasmüller, S., Sutterlüty, H., et al. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.11.009 · Cited by 137
Trompier, D., Chang, X.-B., Barattin, R., d′Hardemare, A. D. M., Pietro, A. D., & Baubichon-Cortay, H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0143 · Cited by 127
Kaplan, O., Navon, G., Lyon, R. C., Faustino, P. J., Straka, E. J., & Cohen, J. S. (1990) · PubMed · Cited by 124
Lyon, R. C., Cohen, J. S., Faustino, P. J., Mégnin-Chanet, F., & Myers, C. E. (1988) · PubMed · Cited by 122
de Avellar, I. G. J., Magalhães, M. M. M., Silva, A. B., Souza, L. L., Leitão, Á. C., & Hermes‐Lima, M. (2004) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2004.08.006 · Cited by 113
Induction by verapamil of a rapid increase in ATP consumption in multidrug‐resistant tumor cells
Broxterman, H. J., Pinedo, H. M., Kuiper, C. M., Kaptein, L. C. M., Schuurhuis, G. J., & Lankelma, J. (1988) · The FASEB Journal · doi:10.1096/fasebj.2.7.3350243 · Cited by 111
Mutoh, K., Tsukahara, S., Mitsuhashi, J., Katayama, K., & Sugimoto, Y. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00300.x · Cited by 109
Jensen, P. B., Holm, B., Sorensen, M., Christensen, I., & Sehested, M. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.154 · Cited by 105
Burkitt, M. J., Milne, L., Nicotera, P., & Orrenius, S. (1996) · Biochemical Journal · doi:10.1042/bj3130163 · Cited by 103
Wu, C., Shukla, S., Calcagno, A. M., Hall, M. D., Gottesman, M. M., & Ambudkar, S. V. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2005 · Cited by 100
Self-citationHeffeter, P., Jakupec, M. A., Körner, W., Chiba, P., Pirker, C., Dornetshuber, R., Elbling, L., Sutterlüty, H., Micksche, M., Keppler, B. K., et al. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.03.002 · Cited by 97
Modulation of membrane drug permeability in Chinese hamster ovary cells
Carlsen, S. A., Till, J. E., & Ling, V. W. T. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90059-6 · Cited by 97
Cell Line Designation Change: Multidrug-Resistant Cell Line in the NCI Anticancer Screen
Scudiero, D. A., Monks, A. P., & Sausville, E. A. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.862 · Cited by 96
Antholine, W. E., Knight, J. M., Whelan, H. T., & Petering, D. H. (1977) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)11190-5 · Cited by 96
A Mechanism for P-Glycoprotein-Mediated Apoptosis As Revealed by Verapamil Hypersensitivity
Karwatsky, J., Lincoln, M. C., & Georges, E. (2003) · Biochemistry · doi:10.1021/bi034149+ · Cited by 87
Perego, P., Romanelli, S., Carenini, N., Magnani, I., Leone, R., Bonetti, A. V., Paolicchi, A., & Zunino, F. (1998) · Annals of Oncology · doi:10.1023/a:1008265012435 · Cited by 86
Dhar, S., Nygren, P., Csóka, K., Botling, J., Nilsson, K., & Larsson, R. L. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.453 · Cited by 83
Verapamil decreases P‐glycoprotein expression in multidrug‐resistant human leukemic cell lines
Muller, C., Bailly, J., Goubin, F., Laredo, J., Jaffrézou, J., Bordier, C., & Laurent, G. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910560523 · Cited by 82
Shen, D.-W., Akiyama, S.-I., Schoenlein, P. V., Pastan, I. H., & Gottesman, M. M. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.134 · Cited by 82
Self-citationModulation of GSH levels in ABCC1 expressing tumor cells triggers apoptosis through oxidative stress
Laberge, R.-M., Karwatsky, J., Lincoln, M. C., Leimanis, M. L., & Georges, E. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.02.005 · Cited by 80
Fiskus, W. C., Rao, R., Fernandez, P., Herger, B. E., Yang, Y., Chen, J., Kolhe, R. B., Mandawat, A., Wang, Y., Joshi, R., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116319 · Cited by 79
Structure of a multidrug transporter
Gottesman, M. M., Ambudkar, S. V., & Xia, D. (2009) · Nature Biotechnology · doi:10.1038/nbt0609-546 · Cited by 77
Self-citationSteroid hormones inhibit binding of alkaloid to multidrug resistance related P-glycoprotein
Naito, M., Yusa, K., & TSURUO, T. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92830-1 · Cited by 70
Arora, A. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh060 · Cited by 69
Effect of chronic exposure to morphine on the rat blood–brain barrier: focus on the P‐glycoprotein
Yousif, S., Saubaméa, B., Cisternino, S., Cynthia Marie-claire, A., Dauchy, S., Scherrmann, J., & Declèves, X. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05647.x · Cited by 66
Megestrol acetate reverses multidrug resistance and interacts with P-glycoprotein
Fleming, G. F., Amato, J. M., Agresti, M., & Safa, A. R. (1992) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00684845 · Cited by 61
Cai, X., Pan, N., & Zou, G. (2006) · BioMetals · doi:10.1007/s10534-006-9008-0 · Cited by 57
Cai, Y., Lu, J., Miao, Z., Lin, L., & Ding, J. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.11.4860 · Cited by 54
Demeule, M., Brossard, M., Turcotte, S., et al. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.09.141 · Cited by 52
Preface: the concept and consequences of multidrug resistance
Sheps, J. A., & Ling, V. W. T. (2006) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-006-0115-0 · Cited by 43
Liang, Y., O’Driscoll, L., McDonnell, S., Doolan, P., Oglesby, I. K., Duffy, K., O'Connor, R. A., & CLYNES, M. M. (2004) · International Journal of Cancer · doi:10.1002/ijc.20230 · Cited by 41
Gupta, R. S. (1985) · PubMed · Cited by 41
Hait, W. N., Choudhury, S., Srimatkandada, S., & Murren, J. R. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116447 · Cited by 40
Prisant, L. M. (2001) · Heart Disease · doi:10.1097/00132580-200101000-00008 · Cited by 40
Screening of an annotated compound library for drug activity in a resistant myeloma cell line
Rickardson, L., Fryknäs, M., Haglund, C., Lövborg, H., Nygren, P., Gustafsson, M. G., Isaksson, A., & Larsson, R. L. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0216-7 · Cited by 39
Rothnie, A. J., Conseil, G., Lau, A. Y. T., Deeley, R. G., & Cole, S. P. C. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.049080 · Cited by 39
The human KB multidrug-resistant cell line KB-C1 is hypersensitive to inhibitors of glycosylation
Bentley, J. (1997) · Cancer Letters · doi:10.1016/s0304-3835(97)04739-3 · Cited by 38
Andō, K., Ohmori, T., Inoue, F., Kadofuku, T., 保坂, 隆., Ishida, H., Shirai, T., Okuda, K., Hirose, T., Horichi, N., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0811 · Cited by 36
Stierlé, V., Laigle, A., & Jollès, B. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.08.007 · Cited by 32
van Triest, B., Pinedo, H. M., Telleman, F., van der Wilt, C. L., Jansen, G., & Peters, G. J. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)82448-3 · Cited by 32
Antitumor Agents 260. New Desmosdumotin B Analogues with Improved In Vitro Anticancer Activity
Nakagawa‐Goto, K., Bastow, K. F., Chen, T.-H., Morris-Natschke, S. L., & Lee, K. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701208v · Cited by 30
Callaghan, R., & Riordan, J. R. (1995) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(95)00042-2 · Cited by 29
Moritaka, T., Kiura, K., Ueoka, H., Tabata, M., Segawa, Y., Shibayama, T., Takigawa, N., Ohnoshi, T., & Harada, M. (1998) · PubMed · Cited by 22
The preferential induction of apoptosis in multidrug-resistant KB cells by 5-fluorouracil
Warr, J. R., Bamford, A. I., & Quinn, D. M. (2002) · Cancer Letters · doi:10.1016/s0304-3835(01)00721-2 · Cited by 18
2-deoxy-D-glucose toxicity and transport in human multidrug-resistant KB carcinoma cell lines.
Bentley, J., Bell, S., Quinn, D. M., Kellett, G. L., & Warr, J. R. (1996) · PubMed · Cited by 17
Cnubben, N. H. P., Wortelboer, H. M., van Zanden, J. J., Rietjens, I. M. C. M., & van BLADEREN, P. J. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.2.219 · Cited by 15
Brewer, F., & Warr, J. R. (1987) · PubMed · Cited by 15
Bergman, A. M., Pinedo, H. M., Veerman, G., Kuiper, C. M., & Peters, G. J. (1998) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-5381-6_114 · Cited by 11
Warr, J. R., Quinn, D., Elend, M., & Fenton, J. A. L. (1995) · Cancer Letters · doi:10.1016/s0304-3835(06)80019-4 · Cited by 8
Cited by
Mechanisms and insights into drug resistance in cancer
Zahreddine, H., & Borden, K. L. B. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00028 · Cited by 660
Role of Reactive Oxygen Species (ROS) in Therapeutics and Drug Resistance in Cancer and Bacteria
Dharmaraja, A. T. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01243 · Cited by 582
Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes
Hall, M. D., Telma, K. A., Chang, K.-E., Lee, T. D., Madigan, J. P., Lloyd, J. R., Goldlust, I. S., Hoeschele, J. D., & Gottesman, M. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0247 · Cited by 377
Self-citationTen things you should know about protein kinases: IUPHAR R eview 14
Fabbro, D., Cowan‐Jacob, S. W., & Moebitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 347
Collateral sensitivity as a strategy against cancer multidrug resistance
Pluchino, K. M., Hall, M. D., Goldsborough, A. S., Callaghan, R., & Gottesman, M. M. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.03.002 · Cited by 305
Self-citation
Metadata
- Authors
- Hall, M. D., Handley, M. D., & Gottesman, M. M.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2009-10
- Volume
- 30
- Issue
- 10
- Pages
- 546-556
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W1977594275
- Cited by
- 259
- References
- 77
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.